Sherrie Urena
Psychiatric/Mental Health · Worcester, MANPI 1245368992
Payments from drug & device makers
Across 806 payments — averaging $26.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$11K
- Alkermes, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$2K
- Johnson & Johnson$1K
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$931
- plus $3K from 15 others
What the payments were for
- Speaking & faculty fees$5,19625%
- Travel & lodging$770%
- Food & beverage$15,39173%
- Education$4272%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 257 | $10,733 |
| Alkermes, Inc. | 90 | $1,907 |
| Otsuka America Pharmaceutical, Inc. | 120 | $1,839 |
| Johnson & Johnson(2 entities) | 59 | $1,267 |
| AbbVie | 71 | $1,036 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 55 | $931 |
| Axsome Therapeutics, Inc. | 25 | $644 |
| Vanda Pharmaceuticals Inc. | 30 | $529 |
| Lundbeck LLC | 28 | $508 |
| Neurocrine Biosciences, Inc. | 18 | $438 |
| E.r. Squibb & Sons, L.L.C. | 10 | $390 |
| Corium, LLC | 17 | $261 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $236 |
| Indivior Inc. | 4 | $111 |
| Vertical Pharmaceuticals, LLC | 3 | $70 |
| Idorsia Pharmaceuticals US Inc | 3 | $61 |
| Lilly USA, LLC | 2 | $59 |
| Braeburn Inc. | 1 | $20 |
| Neos Therapeutics, LP | 1 | $20 |
| Ironshore Pharmaceuticals Inc. | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UZEDY$5,540
- Austedo XR$125
- COBENFY$122
- Auvelity$103
How this compares
$21,091 in reported general payments places this provider in the 95th percentile of 1,284 psychiatric/mental health providers in Massachusetts.
See all psychiatric/mental health providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 18 | $166,223 |
| CaplytaLumateperone Tosylate | 21 | $36,298 |
| SpravatoEsketamine Hcl | 22 | $25,512 |
| VivitrolNaltrexone Microspheres | 14 | $24,094 |
| LybalviOlanzapine/Samidorphan Malate | 13 | $21,997 |
| VyvanseLisdexamfetamine Dimesylate | 15 | $5,980 |
| TrintellixVortioxetine Hydrobromide | 12 | $5,755 |
| Asenapine Maleate | 12 | $5,213 |
| Lisdexamfetamine Dimesylate | 18 | $4,169 |
| ConcertaMethylphenidate Hcl | 11 | $4,105 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 97 | $3,092 |
| Quetiapine Fumarate | 94 | $2,486 |
| Clonazepam | 221 | $2,071 |
| Olanzapine | 92 | $1,919 |
| Aripiprazole | 42 | $1,799 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $10,733 | $166,22318 claims |
| Alkermes, Inc.Vivitrol, Lybalvi | $1,907 | $46,09227 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $931 | $36,29821 claims |
| Johnson & JohnsonSpravato, Concerta | $1,267 | $29,61733 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $236 | $11,73527 claims |
| Lilly USA, LLCOlanzapine | $59 | $1,91992 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,284 psychiatric/mental health providers in Massachusetts.
Other psychiatric/mental health in Worcester
- Kevin NardoneWorcester$16K
- Edward TiminskiWorcester$15K
- Jacquelynne KimaniWorcester$12K
- Hadiza AbubakarWorcester$10K
- Exta TweneboaWorcester$8K
- Orobosa OsawonuyiWorcester$8K
- Stephanie ParentWorcester$7K
- Jamaal HedringtonWorcester$6K
- Bretteney HyppoliteWorcester$6K
- Stephen ZombilWorcester$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.